ArticleJournal of virology2000
Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain.
Article in Journal of virology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 66 citations in OpenAlex.
- Identification of CRF89_BF, a new member of an HIV-1 circulating BF intersubtype recombinant form family widely spread in South America.Scientific reports · 2021Trial
- Trial
- Molecular characterization of recombinant LSDV isolates from 2022 outbreak in Indonesia through phylogenetic networks and whole-genome SNP-based analysis.BMC genomics · 2024Article
- Identification of a HIV-1 circulating BF1 recombinant form (CRF75_BF1) of Brazilian origin that also circulates in Southwestern Europe.Frontiers in microbiology · 2023Article
- Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises.Vaccines · 2020Review
- Analysis and insights into recombination signals in lumpy skin disease virus recovered in the field.PloS one · 2018Article
- Host factors determine differential disease progression after infection with nef-deleted simian immunodeficiency virus.The Journal of general virology · 2014Article
- Near full-length genomic characterization of a HIV type 1 BC recombinant strain from Manipur, India.Virus genes · 2012Article
- Generation and characterization of a defective HIV-1 Virus as an immunogen for a therapeutic vaccine.PloS one · 2012Article
- Review
- Article
- Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge.Journal of virology · 2010Article
- Viral vaccines and CTL response.Journal of biomedicine & biotechnology · 2010Review
- Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus.Virology · 2009Article
- Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.Retrovirology · 2009Article
- Macaques vaccinated with live-attenuated SIV control replication of heterologous virus.The Journal of experimental medicine · 2008Article
- Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus.Proceedings of the National Academy of Sciences of the United States of America · 2004Article
- Rhabdovirus-based vectors with human immunodeficiency virus type 1 (HIV-1) envelopes display HIV-1-like tropism and target human dendritic cells.Journal of virology · 2002Article
- Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector.Journal of virology · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Live, attenuated immunodeficiency virus vaccines, such as nef deletion mutants, are the most effective vaccines tested in the simian immunodeficiency virus (SIV) macaque model. In two independent studies designed to determine the breadth of protection induced by live, attenuated SIV vaccines, we noticed that three of the vaccinated macaques developed higher set point viral load levels than unvaccinated control monkeys. Two of these vaccinated monkeys developed AIDS, while the control monkeys infected in parallel remained asymptomatic. Concomitant with an increase in viral load, a recombinant of the vaccine virus and the challenge virus could be detected. Therefore, the emergence of more-virulent recombinants of live, attenuated immunodeficiency viruses and less-aggressive wild-type viruses seems to be an additional risk of live, attenuated immunodeficiency virus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.